Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Liu, Na ^a   He, Qing Mei ^a   Chen, Jie Wei ^a   Li, Ying Qin ^a   Xu, Ya Fei ^a   Ren, Xian Yue ^a   Sun, Ying ^a   Mai, Hai Qiang ^a   Shao, Jian Yong ^a   Jia, Wei Hua ^a   Kang, Tie Bang ^a   Zeng, Mu Sheng ^a   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cell growth; CIP2A; Nasopharyngeal carcinoma; Proliferation; Survival

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; MESSENGER RNA; MYC PROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AUTOANTIGEN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; MYC PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NASOPHARYNGEAL NEOPLASMS; NUDE MOUSE; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ADULT; AGED; ANIMALS; AUTOANTIGENS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84902084685     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-111     Document Type: Article

References (35)

1. Xu ZJ, Zheng RS, Zhang SW, Zou XN, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2009. Chin J Cancer 2013, 32:453-460. 10.5732/cjc.013.10118, 3845582, 23863562.
2. Cho WC. Most common cancers in Asia-Pacific region: nasopharyngeal carcinoma. Cancer report of Asian-Pacific region 2010 2010, 284-289. Asian Pacific Organization for Cancer Prevention.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
4. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?. Int J Radiat Oncol Biol Phys 2011, 80:661-668. 10.1016/j.ijrobp.2010.03.024, 20643517.
5. Chen Y, Sun Y, Liang SB, Zong JF, Li WF, Chen M, Chen L, Mao YP, Tang LL, Guo Y, Lin AH, Liu MZ, Ma J. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer 2013, 119:2230-2238. 10.1002/cncr.28049, 23576020.
6. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130:51-62. 10.1016/j.cell.2007.04.044, 17632056.
7. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009, 101:793-805. 10.1093/jnci/djp103, 19470954.
8. Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012, 31:4266-4278. 10.1038/onc.2011.599, 22249265.
9. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2008, 15:5092-5100.
10. Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia J, Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 2008, 14:3722-3728. 10.1158/1078-0432.CCR-07-4137, 18559589.
11. Puustinen P, Rytter A, Mortensen M, Kohonen P, Moreira JM, Jäättelä M. CIP2A oncoprotein controls cell growth and autophagy through TORC1 activation. J Cell Biol 2014, 204:713-727. 10.1083/jcb.201304012, 24590173.
12. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011, 18:857-865. 10.1245/s10434-010-1313-8, 20842459.
13. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, Gasser M, Waaga-Gasser AM, Eilers M, Germer CT. CIP2A influences survival in colon cancer and is critical in maintaining Myc expression. PLoS One 2013, 8:e75292. 10.1371/journal.pone.0075292, 3788051, 24098375.
14. Yu G, Liu G, Dong J, Jin Y. Clinical implications of CIP2A protein expression in breast cancer. Med Oncol 2013, 30:524.
15. Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, Ristimäki A. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011, 105:989-995. 10.1038/bjc.2011.346, 3185957, 21897396.
16. Ren J, Li W, Yan L, Jiao W, Tian S, Li D, Tang Y, Gu G, Liu H, Xu Z. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. Br J Cancer 2011, 105:1905-1911. 10.1038/bjc.2011.492, 3251889, 22075943.
17. Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, Atula T, Ristimäki A, Haglund C. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 2011, 104:1890-1895. 10.1038/bjc.2011.167, 3111200, 21610708.
18. Rantanen T, Kauttu T, Akerla J, Honkanen T, Krogerus L, Salo J, Paavonen T, Oksala N. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. Med Oncol 2013, 30:684.
19. Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao R, Yuan Y, Long D, Yang J, Wu Y, Xu H, Liu F, Liu M. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Med Oncol 2013, 30:406.
20. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011, 117:6660-6668. 10.1182/blood-2010-08-304477, 21490338.
21. Khanna A, Pimanda JE, Westermarck J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res 2013, 73:6548-6553. 10.1158/0008-5472.CAN-13-1994, 24204027.
22. Jansens V, Goris J, Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005, 15:34-41. 10.1016/j.gde.2004.12.004, 15661531.
23. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004, 6:171-183. 10.1016/j.ccr.2004.07.009, 15324700.
24. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010, 29:6257-6266. 10.1038/onc.2010.357, 20729919.
25. Kerosuo L, Fox H, Perälä N, Ahlqvist K, Suomalainen A, Westermarck J, Sariola H, Wartiovaara K. CIP2A increases self-renewal and is linked to Myc in neural progenitor cells. Differentiation 2010, 80:68-77. 10.1016/j.diff.2010.04.003, 20447748.
26. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012, 14:R68. 10.1186/bcr3175, 3446403, 22537901.
27. Kim JS, Kim EJ, Oh JS, Park IC, Hwang SG. CIP2A modulates cell cycle progression in human cancer cells by regulating the stability and activity of PLK1. Cancer Res 2013, 73:6667-6678. 10.1158/0008-5472.CAN-13-0888, 23983103.
28. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, Khanna A, Chan EK, Kähäri VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, Westermarck J. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 2013, 3:182-197. 10.1158/2159-8290.CD-12-0292, 3572190, 23306062.
29. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakirpi T, Westermarck J. ETS2 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 2011, 6:e17979. 10.1371/journal.pone.0017979, 3062549, 21445343.
30. Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A, Daugaard M, Valo E, Tuomela S, Bottzauw T, Nielsen CF, Willumsen BM, Hautaniemi S, Lahesmaa R, Westermarck J, Jäättelä M, Kallunki T. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene 2012, 31:390-401. 10.1038/onc.2011.230, 21706057.
31. Pommier Y, Marchand C. Interfacial inhibitors: targeting macromolicular complexes. Nat Rev Drug Discov 2012, 11:25-36.
32. Chan AT, Teo PM, Ngan PK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ. Concurrent chemotherapy-dadiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002, 20:2038-2044. 10.1200/JCO.2002.08.149, 11956263.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
34. Liu N, Cui RX, He QM, Huang BJ, Sun Y, Xie D, Zeng J, Wang HY, Ma J. Reduced expression of Dicer1 is associated with poor prognosis in patients with nasopharyngeal carcinoma. Med Oncol 2013, 30:360.
35. Liu N, Tang LL, Sun Y, Cui RX, Wang HY, Huang BJ, He QM, Jiang W, Ma J. MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett 2013, 329:181-188. 10.1016/j.canlet.2012.10.032, 23142282.